184 related articles for article (PubMed ID: 19164923)
1. Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.
Tribouillard D; Gug F; Galons H; Bach S; Saupe SJ; Blondel M
Prion; 2007; 1(1):48-52. PubMed ID: 19164923
[TBL] [Abstract][Full Text] [Related]
2. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models.
Voisset C; Saupe SJ; Galons H; Blondel M
Infect Disord Drug Targets; 2009 Feb; 9(1):31-9. PubMed ID: 19200013
[TBL] [Abstract][Full Text] [Related]
3. Rational approach to an antiprion compound with a multiple mechanism of action.
Bolognesi ML; Bongarzone S; Aulic S; Ai Tran HN; Prati F; Carloni P; Legname G
Future Med Chem; 2015; 7(16):2113-20. PubMed ID: 26511069
[TBL] [Abstract][Full Text] [Related]
4. Rational targeting for prion therapeutics.
Mallucci G; Collinge J
Nat Rev Neurosci; 2005 Jan; 6(1):23-34. PubMed ID: 15611724
[TBL] [Abstract][Full Text] [Related]
5. Animal models for testing anti-prion drugs.
Fernández-Borges N; Elezgarai SR; Eraña H; Castilla J
Curr Top Med Chem; 2013; 13(19):2504-21. PubMed ID: 24059334
[TBL] [Abstract][Full Text] [Related]
6. Prion chemical biology: on the road to therapeutics?
Chen B; Thompson M; Louth J; Guo K
Curr Top Med Chem; 2013; 13(19):2441-64. PubMed ID: 24059337
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a class of diketopiperazines as antiprion compounds.
Bolognesi ML; Ai Tran HN; Staderini M; Monaco A; López-Cobeñas A; Bongarzone S; Biarnés X; López-Alvarado P; Cabezas N; Caramelli M; Carloni P; Menéndez JC; Legname G
ChemMedChem; 2010 Aug; 5(8):1324-34. PubMed ID: 20540064
[TBL] [Abstract][Full Text] [Related]
8. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.
Hosokawa-Muto J; Kamatari YO; Nakamura HK; Kuwata K
Antimicrob Agents Chemother; 2009 Feb; 53(2):765-71. PubMed ID: 19015328
[TBL] [Abstract][Full Text] [Related]
9. Sigma Receptor Ligands Are Potent Antiprion Compounds that Act Independently of Sigma Receptor Binding.
Mercer RCC; Le NTT; Fraser DG; Houser MCQ; Beeler AB; Harris DA
ACS Chem Neurosci; 2024 Jun; 15(11):2265-2282. PubMed ID: 38743607
[TBL] [Abstract][Full Text] [Related]
10. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.
Bertsch U; Winklhofer KF; Hirschberger T; Bieschke J; Weber P; Hartl FU; Tavan P; Tatzelt J; Kretzschmar HA; Giese A
J Virol; 2005 Jun; 79(12):7785-91. PubMed ID: 15919931
[TBL] [Abstract][Full Text] [Related]
11. Protein folding activity of the ribosome (PFAR) -- a target for antiprion compounds.
Banerjee D; Sanyal S
Viruses; 2014 Oct; 6(10):3907-24. PubMed ID: 25341659
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.
Tribouillard-Tanvier D; Béringue V; Desban N; Gug F; Bach S; Voisset C; Galons H; Laude H; Vilette D; Blondel M
PLoS One; 2008 Apr; 3(4):e1981. PubMed ID: 18431471
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity.
Lim YB; Mays CE; Kim Y; Titlow WB; Ryou C
Biomaterials; 2010 Mar; 31(8):2025-33. PubMed ID: 20022103
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease.
Thompson MJ; Louth JC; Ferrara S; Sorrell FJ; Irving BJ; Cochrane EJ; Meijer AJ; Chen B
ChemMedChem; 2011 Jan; 6(1):115-30. PubMed ID: 21154498
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of cerebral neurodegeneration in prion diseases.
Tatzelt J; Schätzl HM
FEBS J; 2007 Feb; 274(3):606-11. PubMed ID: 17288549
[TBL] [Abstract][Full Text] [Related]
16. Prions: protein aggregation and infectious diseases.
Aguzzi A; Calella AM
Physiol Rev; 2009 Oct; 89(4):1105-52. PubMed ID: 19789378
[TBL] [Abstract][Full Text] [Related]
17. Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures.
Cronier S; Beringue V; Bellon A; Peyrin JM; Laude H
J Virol; 2007 Dec; 81(24):13794-800. PubMed ID: 17913812
[TBL] [Abstract][Full Text] [Related]
18. A yeast-based assay to isolate drugs active against mammalian prions.
Bach S; Tribouillard D; Talarek N; Desban N; Gug F; Galons H; Blondel M
Methods; 2006 May; 39(1):72-7. PubMed ID: 16750390
[TBL] [Abstract][Full Text] [Related]
19. Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding.
Choi J; Govindaraj RG; Hyeon JW; Lee K; Ma S; Kim SY; Lee J; No KT
Chem Biol Drug Des; 2017 Jun; 89(6):907-917. PubMed ID: 27933736
[TBL] [Abstract][Full Text] [Related]
20. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
